Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Aspirin in Reduction of Tension II Study

First Posted Date
2011-06-23
Last Posted Date
2014-05-14
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
290
Registration Number
NCT01379079
Locations
🇳🇱

Leiden University Medical Center, Leiden, Netherlands

Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

Not Applicable
Conditions
First Posted Date
2011-06-17
Last Posted Date
2011-06-21
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
50
Registration Number
NCT01375400
Locations
🇫🇷

Hopital central, Nancy, France

Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-06-16
Last Posted Date
2013-05-14
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
100
Registration Number
NCT01374698
Locations
🇮🇹

Sapienza University of Rome, Rome, Italy

Genotypic and Phenotypic Correlates of Resistance to Aspirin

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-05-27
Last Posted Date
2013-12-16
Lead Sponsor
George Washington University
Target Recruit Count
190
Registration Number
NCT01361620
Locations
🇺🇸

GWU Medical Faculty Associates, Washington, District of Columbia, United States

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

First Posted Date
2011-05-18
Last Posted Date
2018-09-18
Lead Sponsor
Michaela Liedtke
Target Recruit Count
14
Registration Number
NCT01355705
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-05-12
Last Posted Date
2016-11-01
Lead Sponsor
Kaohsiung Veterans General Hospital.
Target Recruit Count
178
Registration Number
NCT01353144
Locations
🇨🇳

Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

🇨🇳

Chung-Ho Hospital, Kaohsiung, Taiwan

Clopidogrel and Aspirin Interaction Study-2

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-04-26
Last Posted Date
2023-07-27
Lead Sponsor
Population Health Research Institute
Target Recruit Count
302
Registration Number
NCT01341964
Locations
🇨🇦

Population Health Research Institute, Hamilton General Hospital, Hamilton, Ontario, Canada

Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease

Phase 2
Conditions
Interventions
First Posted Date
2011-04-04
Last Posted Date
2012-12-25
Lead Sponsor
Medical University of Vienna
Target Recruit Count
74
Registration Number
NCT01328145
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder

First Posted Date
2011-03-23
Last Posted Date
2011-03-23
Lead Sponsor
Sheba Medical Center
Target Recruit Count
400
Registration Number
NCT01320982
Locations
🇷🇴

Clinica de Psihiatrie, Arad, Romania

🇷🇴

Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia", Bucuresti, Romania

🇷🇴

Sp. Jud. "Prof. Dr.O. Fodor", Cluj-Napoca, Romania

and more 4 locations

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

First Posted Date
2011-01-21
Last Posted Date
2023-08-23
Lead Sponsor
Biogen
Target Recruit Count
56
Registration Number
NCT01281111
Locations
🇺🇸

Research Site, Saint Paul, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath